ECG Manifestations: 
The Poisoned Patient

Christopher P. Holstege, MD*, David L. Eldridge, MD, Adam K. Rowden, DO

Division of Medical Toxicology, Department of Emergency Medicine, University of Virginia, P.O. Box 800774, Charlottesville, VA 22908-0774, USA

Emergency physicians routinely evaluate and manage poisoned patients. In 2003, more than 2 million human exposure cases were reported to poison centers throughout the United States [1]. Of those cases, 22% were treated in a health care facility with most of those cases evaluated in the emergency department. Cardiovascular drugs were listed as the fifteenth most frequently encountered human exposure (66,401) and the fifth leading cause of poisoning deaths.

Drug-induced changes and abnormalities on the 12-lead electrocardiogram (ECG) are common. There are numerous drugs that can cause ECG changes and lead to cardiac dysrhythmias. The diagnoses and subsequent management of patients manifesting ECG changes following poisonings can challenge even the most experienced physician. Drugs that are advocated in Advanced Coronary Life Support protocols for cardiac dysrhythmias may not apply or may even worsen the condition of overdose patients [2].

Despite that drugs have widely varying indications for therapeutic use, many unrelated drugs share a common cardiac pharmacologic effect if taken in overdose. The purpose of this article is to group together agents that cause similar electrocardiographic effects, review their pharmacologic actions, and discuss the electrocardiographic findings reported in the medical literature. The five main categories reviewed include potassium (K+) efflux blockers, sodium (Na+) channel blockers, sodium-potassium adenosine-tri-phosphatase (Na+/K+ ATPase) blockers, calcium channel blockers (CCB), and beta-adrenergic blockers (BB). It is important to keep in mind, however, that many medications have actions that involve more than one of these
actions, and thus may result in a combination or myriad of electrocardiographic changes.

**Cardiac physiology**

To understand the ECG changes associated with various drugs, physicians must have a clear understanding of basic myocardial cell function. The myocardial cell membrane in its resting state is impermeable to Na$^+$ (Fig. 1). The Na$^+$/K$^+$ ATPase actively pumps three sodium ions out of cardiac cells while pumping in two potassium ions to maintain a negative electric potential of approximately 90 mV in the myocyte (phase 4). Depolarization of the cardiac cell membrane is caused by the rapid opening of Na$^+$ channels and subsequent massive Na$^+$ influx (phase 0). This Na$^+$ influx causes the rapid upstroke of the cardiac action potential as it is conducted through the ventricles and is directly responsible for the QRS interval of the ECG. The peak of the action potential is marked by the closure of Na$^+$ channels and the activation of K$^+$ efflux channels (phase 1). Calcium (Ca$^{++}$) influx then occurs, allowing for a plateau in the action potential (phase 2) and continued myocardial contraction. The cardiac cycle ends with closure of the Ca$^{++}$ channels and activation of K$^+$ efflux channels, causing the potential to again approach −90 mV (phase 3). It is this potassium efflux from the myocardial cell that is directly responsible for the QT interval on the ECG [3].

![Fig. 1. Cardiac cycle action potential with corresponding electrocardiographic tracing. Dotted line indicates the changes associated with Na$^+$ channel blocker toxicity. Dashed line indicates the changes associated with K$^+$ efflux blocker toxicity.](image-url)
Potassium efflux blocker toxicity

Background

Medications in the K+ efflux blocker category are listed in Table 1. These medications all block the outward flow of potassium from intracellular to extracellular spaces. Myocardial repolarization is driven predominantly by this outward movement of potassium ions [3]. Blockade of the outward potassium currents by drugs may prolong the cardiac cycle action potential (Fig. 1) [4]. As a result, the primary electrocardiographic manifestation of potassium efflux blocker toxicity is QT interval prolongation. In fact, studies suggest that approximately 3% of total noncardiac prescriptions are associated with the potential for QT interval prolongation [5].

These medications vary in their propensity to induce QT interval prolongation or associated dysrhythmias at therapeutic and toxic levels. Some of these drugs, such as sotalol, are marketed specifically for their ability to inhibit this delayed rectifier current [6]. Other medications possess this activity as an unwelcome side effect at therapeutic doses. Several medications, such as terfenadine and cisapride, have been removed from the market in various countries because of reports of associated torsades de pointes and sudden death in patients taking these drugs [7,8]. Other medications in this class rarely have been reported to cause QT interval prolongation except when taken in massive overdose.

In addition, many of these drugs have other effects that can result in significant cardiovascular and electrocardiographic changes. For example, antipsychotic agents can cause muscarinic acetylcholine receptor and alpha-adrenergic receptor blockade and cardiac cell potassium, sodium, and calcium channel blockade.

Electrocardiographic manifestations

As noted, the primary electrocardiographic manifestation of K+ efflux blocker toxicity is QT interval prolongation (Fig. 2). When measuring the QT interval, the ECG is best recorded at a paper speed of 50 mm/sec and an amplitude of 0.5 mV/cm (the latter is equal to 20 mm/mV; the usual settings are 25 mm/sec and 10 mm/mV). A tangent line then is drawn to the steepest part of the descending portion of the T wave. The intercept between that line and the isoelectric line is defined as the end of the T wave. The QT interval then is measured from the beginning of the QRS complex to the end of the T wave. Within any ECG tracing, there is lead-to-lead variation of the QT interval. In general, the longest measurable QT interval on an ECG is regarded as determining the overall QT interval for a given tracing [9]. The QT interval is influenced by the patient’s heart rate. The RR interval should be measured to allow for rate correction. Several formulas have been developed to correct the QT interval for the effect of heart rate (QTc), with Bazett’s formula ($\text{QTc} = \text{QT} / \sqrt{\text{RR}}$) being the most commonly
### Table 1

**K\(^+\) efflux channel blocking drugs**

<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antihistamines</td>
<td>Astemizole, Diphenhydramine, Loratidine, Terfenadine</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Chlorpromazine, Droperidol, Haloperidol, Mesoridazine, Pimozide, Quetiapine, Risperidone, Thioridazine, Ziprasidone</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>Bepridil, Chloroquine, Cisapride, Citalopram</td>
</tr>
<tr>
<td>Class IA antidysrhythmics</td>
<td>Disopyramide, Quinidine, Procainamide, Encaainide, Flecainide, Moricizine, Propafenone</td>
</tr>
<tr>
<td>Class IC antidysrhythmics</td>
<td>Encainide, Flecainide, Moricizine, Propafenone</td>
</tr>
<tr>
<td>Class III antidysrhythmics</td>
<td>Amiodarone, Dofetilide, Ibutilide, Sotalol</td>
</tr>
<tr>
<td>Cyclic antidepressants</td>
<td>Amitriptyline, Amoxapine, Desipramine, Doxepin, Imipramine, Nortriptyline, Maprotiline</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Ciprofloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, Sparfloxacin, Halofantrine, Hydroxychloroquine, Levomethadyl</td>
</tr>
</tbody>
</table>
used. QT interval prolongation is considered to occur when the QTc interval is greater than 0.44 seconds in men and 0.46 seconds in women.

The potential risk for QT interval prolongation with this class of medications is not simply related to a drug dose or concentration. Other factors also influence the QT interval, such as the patient’s sex and electrolyte concentrations. In addition to QT interval prolongation, there is also the potential emergence of T- or U-wave abnormalities on the ECG with this class of medications [10].

Moreover, delay of repolarization causes the myocardial cell to have less charge difference across its membrane. This change can result in activation of the inward depolarization current (early after-depolarization), which may in turn promote triggered activity. This triggered activity potentially can progress to re-entry and subsequent polymorphic ventricular tachycardia, or torsades de pointes [11]. These dysrhythmias are associated most commonly with QT intervals greater than 0.50 seconds, although the potential for dysrhythmia for a given QT interval varies from drug to drug and patient to patient [3]. In addition, there is not a simple relationship between the degree of drug-induced QT interval prolongation and the potential for

<table>
<thead>
<tr>
<th>Table 1 (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrolides</td>
</tr>
<tr>
<td>Clarithromycin</td>
</tr>
<tr>
<td>Erythromycin</td>
</tr>
<tr>
<td>Pentamidine</td>
</tr>
<tr>
<td>Quinine</td>
</tr>
<tr>
<td>Tacrolimus</td>
</tr>
<tr>
<td>Venlafaxine</td>
</tr>
</tbody>
</table>

**Table 1 (continued)**

**Macrolides**
- Clarithromycin
- Erythromycin

**Pentamidine**

**Quinine**

**Tacrolimus**

**Venlafaxine**

---

**Fig. 2.** K⁺ efflux blocker toxicity. Note the marked QT interval prolongation on this 12-lead ECG; hydroxychloroquine was the offending agent.
the occurrence of torsades de pointes. Drug-induced torsades de pointes can occur even without any substantial prolongation of the QT interval [3].

Similar to other members of this class, antipsychotic agents can cause significant QT interval prolongation and associated dysrhythmias. Additionally, other ECG abnormalities can be seen as a result of other actions of these agents. **QRS complex widening** can occur as a result of **Na⁺ channel blockade** (see later discussion). Sinus tachycardia can occur because of the anticholinergic effect of these medications and from the reflex tachycardia induced by alpha-adrenergic blockade in the peripheral vasculature.

**Management**

If a patient has drug-induced QT interval prolongation, therapy should focus on immediate withdrawal of the potential cause and correction of any coexisting medical problems, such as electrolyte abnormalities. Patients who have newly diagnosed drug-induced prolongation of their QT interval should be considered candidates for admission to a monitored setting. Intravenous magnesium sulfate is a highly effective and benign intervention to suppress occurrence of dysrhythmias associated with QT interval prolongation, even though it typically does not result in shortening of the QT interval itself [12]. In patients who have intermittent runs of torsades de pointes not responsive to magnesium therapy, electrical overdrive pacing should be considered. In the presence of a non-perfusing rhythm, such as ventricular fibrillation, pulseless ventricular tachycardia, or torsades de pointes, unsynchronized electrical defibrillation should be performed.

**Sodium channel blocker toxicity**

**Background**

The ability of drugs to induce cardiac sodium (Na⁺) channel blockade has been well described in numerous literature reports [13]. This Na⁺ channel blockade activity has been described as a membrane stabilizing effect, a local anesthetic effect, or a quinidine-like effect. Cardiac voltage-gated sodium channels reside in the cell membrane and open in response to depolarization of the cell (Fig. 1). The Na⁺ channel blockers bind to the transmembrane Na⁺ channels and decrease the number available for depolarization. This creates a delay of Na⁺ entry into the cardiac myocyte during phase 0 of depolarization. As a result, the upslope of depolarization is slowed and the QRS complex widens. Myocardial Na⁺ channel blocking drugs comprise a diverse group of pharmaceutical agents (Table 2). Specific drugs may affect not only the myocardial Na⁺ channels, but also other myocardial ion channels, such as the calcium influx and potassium efflux. This may result in ECG changes and rhythm disturbances not related entirely to the drug’s Na⁺ channel blocking activity. For example, sodium
channel blocking medications such as diphenhydramine, propoxyphene, and cocaine also may develop anticholinergic, opioid, and sympathomimetic syndromes, respectively [14–16]. Similarly, cyclic antidepressant toxicity results not only from myocyte sodium channel blockade, but also from their action with respect to alpha-adrenergic blockade, muscarinic anticholinergic effects, and presynaptic neurotransmitter reuptake inhibition.

Electrocardiographic manifestations

As a result of its action in slowing the upslope of depolarization in the cardiac cycle, Na+ channel blockers result in widening of the QRS complex (Fig. 3) [17]. In some cases, the QRS complexes may take the pattern of recognized bundle branch blocks [18,19]. In the most severe cases, the QRS prolongation becomes so profound that it is difficult to distinguish between
ventricular and supraventricular rhythms [20,21]. Continued prolongation of the QRS complex may result in a sine wave pattern (Fig. 4) and eventual asystole.

Sodium channel blockers also may induce ventricular tachycardia [22]. It has been theorized that the Na\(^+\) channel blockers can cause slowed intraventricular conduction, unidirectional block, the development of a re-entrant circuit, and a resulting ventricular tachycardia (Fig. 5). These

---

**Fig. 3.** Na\(^+\) channel blocker poisoning. 12-lead ECG demonstrating QRS complex widening and tachycardia as a result of tricyclic antidepressant overdose.

**Fig. 4.** Na\(^+\) channel blocking agent toxicity. 12-lead ECG demonstrating sine wave pattern following overdose; atrial and ventricular activity are difficult to distinguish.
rhythms then can degenerate into ventricular fibrillation. Because many of the Na\textsuperscript{+} channel blocking agents are also anticholinergic or sympathomimetic agents, bradydysrhythmias are rare. The Na\textsuperscript{+} channel blocking agents, however, can affect cardiac pacemaker cells. Bradycardia may occur because of slowed depolarization of pacemaker cells that depend on entry of sodium ions. In Na\textsuperscript{+} channel blocker poisoning by anticholinergic and sympathomimetic drugs, the combination of a wide QRS complex and bradycardia is an ominous sign and may indicate that the Na\textsuperscript{+} channel blockade is so profound that tachycardia does not occur, despite clinical muscarinic antagonism or adrenergic agonism [13].

In this class of agents, cyclic antidepressants produce several ECG changes related to Na\textsuperscript{+} channel blockade and their other actions on cardiovascular function (see Fig. 3). Sinus tachycardia occurs frequently from the anticholinergic effects of cyclic antidepressant toxicity. QRS complex widening occurs as a result of Na\textsuperscript{+} blockade, and this delayed conduction may be seen more commonly involving the right side of the heart, manifesting as a right bundle branch block [23]. In addition, QT interval prolongation can occur with these agents. Finally, rightward axis deviation of the terminal 40 msec (0.04 seconds) of the frontal plane QRS axis has been associated with tricyclic antidepressant poisoning [24,25]. The occurrence of this finding in other Na\textsuperscript{+} channel blocking agents is unknown.

Cocaine is a unique sympathomimetic agent in its ability to cause cardiac Na\textsuperscript{+} channel blockade. Together with QRS complex widening, increased catecholamine activity seen with cocaine toxicity can result in several rhythm disturbances, including sinus tachycardia, premature ventricular contractions, wide complex dysrhythmias, ventricular tachycardia, and ventricular fibrillation. In addition, morphologic changes in the ST segment and T waves consistent with ischemia can be seen in the setting of sympathomimetic and cocaine toxicity.

**Management**

The management of Na\textsuperscript{+} channel blocking agents consists of administration of sodium or creation of an alkalosis [26–30]. Infusion of sodium bicarbonate by intermittent bolus or by continuous infusion has been advocated. Hypertonic sodium infusion and hyperventilation also have been advocated.
Reasonable, literature-supported indications for sodium bicarbonate infusion include a QRS duration of >0.10 seconds, persistent hypotension despite adequate hydration, and ventricular dysrythmias. Lidocaine has been suggested in the treatment of ventricular dysrythmias, though clear evidence is lacking. Class IA and IC antidysrythmics should be avoided because of their ability to block cardiac sodium channels.

**Sodium–potassium ATPase blocker toxicity**

*Background*

Cardiac glycosides are agents that inhibit the sodium–potassium adenosine triphosphatase (Na+/K+ ATPase) pump. Digoxin and other digitalis derivatives are the cardiac glycosides encountered most widely, but numerous other similar acting agents also exist (Box 1). Digoxin historically has been administered to treat supraventricular tachydysrythmias and congestive heart failure, but its use has been decreasing as newer agents have been developed. Nonprescription medication cardiac glycosides also have been associated with human toxicity, such as after ingestion of specific plants and contaminated herbal products [35–40].

The cardiac glycosides inhibit active transport of Na+ and K+ across cell membranes by inhibiting the Na+/K+ ATPase. This results in an increase in extracellular K+ and intracellular Na+. An increased intracellular Na+ reduces the transmembrane Na+ gradient and subsequent increased activity of the Na+-Ca²⁺ exchanger. This activity, in turn, increases the intracellular calcium concentration, which then augments myofibril activity in cardiac myocytes and results in a positive inotropic effect. The cardiac glycosides also increase vagal tone that may lead to a direct atrioventricular (AV) nodal depression. Therapeutically, digitalis derivatives are used to increase myocardial contractility or slow AV conduction. These actions, however, can result in significant cardiac disturbances and ECG abnormalities in the setting of toxicity.

**Box 1. Na+/K+ ATPase blocking agents and substances**

| Bufadienolides | Digoxin | Digitoxin | Foxglove | Lily of the valley | Oleander | Red squill |
Electrocardiographic manifestations

Digitalis derivatives at therapeutic doses have been associated with several electrocardiographic changes. These findings include the so-called “digitalis effect” manifesting with abnormal inverted or flattened T waves coupled with ST segment depression, frequently described as a sagging or scooped ST segment/T wave complex. These findings are most pronounced in leads with tall R waves. In addition, other findings include QT interval shortening as a result of decreased ventricular repolarization time, PR interval lengthening as a result of increased vagal activity, and increased U-wave amplitude. It is important to remember that these electrocardiographic manifestations are seen with therapeutic digoxin levels and do not correlate with toxicity.

Electrocardiographic abnormalities with cardiac glycoside toxicity are the result of the propensity for increased automaticity (from increased intracellular calcium) accompanied by slowed conduction through the AV node. As a result, cardiac glycoside toxicity may result in a wide array of dysrhythmias [41,42]. Excitant activity (atrial, junctional, and ventricular premature beats, tachydysrhythmias, and triggered dysrhythmias), suppressant activity (sinus bradycardia, bundle branch blocks, first-, second-, and third-degree AV blocks), and any combination of excitant and suppressant activity (atrial tachycardia with AV block, second-degree AV block with junctional premature beats) have all been reported (Fig. 6) [43–45].

The most common dysrhythmia associated with toxicity induced by these agents is frequent premature ventricular beats [42]. Paroxysmal atrial tachycardia with variable block or accelerated junctional rhythm is highly suggestive of digitalis toxicity. Marked slowing of the ventricular response in a patient who has atrial fibrillation who is on digoxin should suggest the possibility of toxicity (Fig. 6). Bidirectional ventricular tachycardia is stated to be specific for digitalis toxicity, but rarely is seen [46].

Fig. 6. Na+/K+ ATPase blocker toxicity. 12-lead ECG demonstrating an irregular bradydysrhythmia as a result of conduction block from chronic digoxin toxicity.
The ECG may demonstrate findings associated not only with cardiac glycoside toxicity but also with hyperkalemia. Acute toxicity most closely correlates with hyperkalemia as the Na+/K+ ATPase is inhibited and extracellular K+ increases. In chronic toxicity, hyperkalemia may not be seen because of the slower increase in K+, allowing for renal compensation.

Management

In cardiac glycoside toxicity, digoxin-specific antibody (Fab) fragments are the first-line therapy in patients who have symptomatic cardiac dysrhythmias [41,47]. Because cardiac glycoside-enhanced vagal activity may be reversed by atropine sulfate, this agent has been used successfully in patients exhibiting AV block on ECG [48]. Cardiac pacing has been advocated for bradydysrhythmias unresponsive to atropine, but care should be exercised as the pacing wire itself may induce ventricular fibrillation [49]. The classic antidysrhythmic of choice for ventricular dysrhythmias is phenytoin, because it increases the ventricular fibrillation threshold in the myocardium and enhances conduction through the AV node [41]. Quinidine and procainamide are contraindicated because they depress AV nodal conduction and may worsen cardiac toxicity [50].

Calcium channel blocker toxicity

Background

There are currently nine cardiac calcium channel blockers (CCBs) that have been approved for clinical use in the United States. These nine are subclassified within four classes of compounds (Box 2). Over the past decade,

<table>
<thead>
<tr>
<th>Box 2. Ca++ channel blocking drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dihydropyridines</strong></td>
</tr>
<tr>
<td>Nicardipine</td>
</tr>
<tr>
<td>Nifedipine</td>
</tr>
<tr>
<td>Isradipine</td>
</tr>
<tr>
<td>Amlodipine</td>
</tr>
<tr>
<td>Felodipine</td>
</tr>
<tr>
<td>Nimodipine</td>
</tr>
<tr>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td>Verapamil</td>
</tr>
<tr>
<td>Benzothiazepine</td>
</tr>
<tr>
<td>Diltiazem</td>
</tr>
<tr>
<td>Diarylaminopropylamine ether</td>
</tr>
<tr>
<td>Bepridil</td>
</tr>
</tbody>
</table>
the number of exposures to these agents has increased dramatically as they have become available on the market. In 2001, CCBs accounted for 40% of all the deaths caused by cardiovascular drugs reported to the AAPCC [51].

All cardiac CCBs inhibit the voltage sensitive L-type calcium channel within the cell membrane [52]. This channel resides in heart and smooth muscle cell membranes. The inhibition of this channel prevents movement of calcium from extracellular sites through the cell membrane to intracellular sites. Decreased intracellular calcium within the myocardial cells results in slowing of conduction, decreased contractility, and decreased cardiac output.

Blockade of calcium influx within the vascular smooth muscle cells results in vasodilation. Decreased cardiac output coupled with vasodilation can result in profound hypotension. The dihydropyridine class of drugs tends to have a higher affinity for the peripheral vascular smooth muscle cells, less effect on the cardiac calcium channels, and is associated more often with hypotension with a resulting reflex tachycardia. Verapamil and diltiazem, on the other hand, have strong affinity for cardiac and vascular calcium channels and subsequently the combination of hypotension with bradycardia may be seen. In animal models and human case series, CCBs also have been associated with cardiac sodium channel blockade [53,54].

**Electrocardiographic manifestations**

The inhibition of calcium influx within the conduction system results in slowing of cardiac conduction. CCB toxicity initially causes a sinus bradycardia that may or may not be symptomatic. Depending on the agent ingested, reflex tachycardia may not be seen. As levels of CCB increase, the patient may develop various degrees of AV block (first-, second-, and third-degree) and junctional and ventricular bradydysrhythmias on ECG (Fig. 7). A widening of the QRS complex may be encountered. This may be caused by ventricular escape rhythms or by CCB-induced sodium channel blockade causing a delay of phase 0 of depolarization. This delay and subsequent QRS complex widening also increases the potential for dysrhythmias (see the previous section on Sodium channel blocker toxicity)

---

**Fig. 7. CCB toxicity. 12-lead ECG demonstrating a marked bradydysrhythmia with a heart rate in the thirties.**
[53,54]. In the final stages, asystole may occur. Sudden shifts from brady-dysrhythmias to cardiac arrest have been reported [53]. In addition, ECG changes associated with cardiac ischemia may occur as a result of the hypotension and changes in cardiovascular status, particularly in patients who have pre-existing cardiac disease.

Management

A symptomatic acute CCB overdose can be one of the most challenging poisonings encountered by a physician. CCB poisonings are prone to developing severe bradydysrhythmias and hypotension and other complications, including pulmonary edema and heart failure [55]. Specific pharmacologic therapy includes the use of atropine, calcium, glucagon, insulin, sodium bicarbonate, or various catecholamines [56,57].

Beta-adrenergic blocker toxicity

Background

BBs are used increasingly because of their efficacy in the treatment of hypertension, ischemic heart disease, and dysrhythmias. BBs competitively inhibit various β-adrenergic receptors. Inhibition of β1-receptors results in a decrease in the force and rate of myocardial contraction, a decrease in AV nodal conduction velocity, and a decrease in renin secretion. Inhibition of β2-receptors results in a decrease in glycogenolysis, decrease in gluconeogenesis, and decrease in relaxation of smooth muscles in blood vessels, bronchi, and the gastrointestinal tract. There are currently numerous BBs available (Box 3). These agents share in common the mechanism of

<table>
<thead>
<tr>
<th>Box 3. Beta-adrenergic blocking drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acebutolol</td>
</tr>
<tr>
<td>Atenolol</td>
</tr>
<tr>
<td>Betaxolol</td>
</tr>
<tr>
<td>Bisoprolol</td>
</tr>
<tr>
<td>Carvedilol</td>
</tr>
<tr>
<td>Esmolol</td>
</tr>
<tr>
<td>Labetalol</td>
</tr>
<tr>
<td>Metoprolol</td>
</tr>
<tr>
<td>Nadolol</td>
</tr>
<tr>
<td>Pindolol</td>
</tr>
<tr>
<td>Propranolol</td>
</tr>
<tr>
<td>Sotalol</td>
</tr>
<tr>
<td>Timolol</td>
</tr>
</tbody>
</table>
competitive β-adrenergic receptor antagonism. Some of these agents have equal affinity for β₁ and β₂ receptors (eg, propranolol), whereas others are selective and have greater β₁ than β₂ receptor blocking activity (eg, metoprolol). Some agents also block other receptors, such as α-adrenergic receptors (eg, labetalol), cardiac sodium channels (eg, propranolol, acebutolol), and cardiac potassium efflux channels (eg, sotalol) [58,59].

Electrocardiographic manifestations

In acute overdose, the most pronounced effects of BBs are on the cardiovascular system [60]. Bradycardia (from decreased sinoatrial node function), varying degrees of AV block, and hypotension are generally the hallmarks of significant beta-blocker toxicity. One prospective study attempted to characterize electrocardiographic findings in symptomatic BB overdose [61]. Only 3 of 13 symptomatic patients had bradycardia on their initial ECG (performed while they were classified as symptomatic). First-degree AV block was common, however. In fact, 10 of 12 symptomatic patients with a measurable PR interval (the thirteenth patient had atrial fibrillation) demonstrated a first-degree AV block and had a mean PR interval of 0.22 seconds. This finding was the most common abnormality to be found on electrocardiograms in this symptomatic patient group.

Besides bradycardia and AV block, there are other specific findings that can be seen with individual members within this group of medications. Propranolol is unique because of its Na⁺ channel blocking activity in overdose that can result in a prolonged QRS interval (>0.10 seconds) [58,61–63]. Propranolol overdose has been associated with a higher mortality rate compared with other BBs [66]. These same investigators also found that a QRS interval >0.10 seconds in these patients was predictive of propranolol-induced seizures. Sotalol is a unique BB in that it possesses the ability to block delayed rectifier potassium channels in a dose-dependent fashion [64]. Acebutolol preferentially blocks β₁ receptors and possesses partial agonist activity and membrane stabilizing activity similar to propranolol. QRS interval widening on ECG and ventricular tachycardia have been reported in several cases [59,65,66].

Management

Specific pharmacologic therapy for BB toxicity may include atropine, glucagon, calcium, insulin, or various catecholamines [67]. Atropine may be considered in an attempt to reverse bradycardia, but has been shown to have poor effect and no impact on blood pressure. Glucagon infusion, which increases intracellular cAMP, should be considered in symptomatic BB toxic patients [60]. Calcium has been shown to have efficacy at reversing the hypotensive effects of BB toxicity in animal models and human case reports [60,68]. Insulin infusions have been advocated for BB toxicity based on an
animal model [69]. Catecholamine infusions may be considered after the therapies discussed previously fail to give adequate response. Pacemaker insertion, balloon pump, and bypass all may be considered in cases not responding to pharmacologic therapy.

Summary

Toxicologic, medication- and drug-induced changes and abnormalities on the 12-lead electrocardiogram (ECG) are common. A wide variety of electrocardiographic changes can be seen with cardiac and noncardiac agents and may occur at therapeutic or toxic drug levels. In many instances, however, a common mechanism affecting the cardiac cycle action potential underlies most of these electrocardiographic findings. Knowledge and understanding of these mechanisms and their related affect on the 12-lead ECG can assist the physician in determining those ECG abnormalities associated with specific toxidromes.

References


